Status and phase
Conditions
Treatments
About
This randomized controlled trial will test the hypothesis that oral Clonidine or Doxazosin improves nightmares (primary outcome), other PTSD symptoms and psychopathology (secondary outcomes) to a greater extent than placebo over a ten week intervention phase in a parallel group design.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
189 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Stefanie Koglin, MD; Stefan Roepke, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal